Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. The company's lead products consist of four ophthalmology development programs across three targets, including X-linked retinoschisis that is in Phase I/II clinical trials; X-linked retinitis pigmentosa, which is in Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials for the treatment of inherited retinal diseases, as well as a preclinical program in adrenoleukodystrophy, which is a disease of the central nervous system and otology. It has collaboration agreements with Biogen MA, Inc., Synpromics Limited, and Bionic Sight, LLC, as well as the University of Florida Research Foundation. The company was founded in 1999 and is headquartered in Alachua, Florida.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone386-462-2204
Debt
Current Ratio4.32
Quick Ratio4.32
Price-To-Earnings
Sales & Book Value
Annual Sales$24.19 million
Price / Sales2.28
Price / Cash FlowN/A
Price / Book0.55
Profitability
Net Income$-21,300,000.00
Net Margins-67.02%
Return on Assets-15.19%
Miscellaneous
Employees78
OptionableOptionable
Applied Genetic Technologies (NASDAQ:AGTC) Frequently Asked Questions
What is Applied Genetic Technologies' stock symbol?
Applied Genetic Technologies trades on the NASDAQ under the ticker symbol "AGTC."
How were Applied Genetic Technologies' earnings last quarter?
Applied Genetic Technologies Corp (NASDAQ:AGTC) announced its quarterly earnings results on Thursday, November, 8th. The biotechnology company reported $0.07 EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.50) by $0.57. The biotechnology company earned $14.03 million during the quarter, compared to analyst estimates of $2.90 million. Applied Genetic Technologies had a negative return on equity of 18.97% and a negative net margin of 67.02%. View Applied Genetic Technologies' Earnings History.
When is Applied Genetic Technologies' next earnings date?
What price target have analysts set for AGTC?
6 Wall Street analysts have issued twelve-month target prices for Applied Genetic Technologies' stock. Their predictions range from $5.00 to $15.00. On average, they anticipate Applied Genetic Technologies' stock price to reach $8.00 in the next year. This suggests a possible upside of 163.2% from the stock's current price. View Analyst Price Targets for Applied Genetic Technologies.
What is the consensus analysts' recommendation for Applied Genetic Technologies?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Applied Genetic Technologies in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Applied Genetic Technologies.
Has Applied Genetic Technologies been receiving favorable news coverage?
Media stories about AGTC stock have been trending somewhat negative this week, according to InfoTrie. The research group identifies negative and positive media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Applied Genetic Technologies earned a news impact score of -1.6 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the immediate future.
Who are some of Applied Genetic Technologies' key competitors?
Some companies that are related to Applied Genetic Technologies include Adverum Biotechnologies (ADVM), LogicBio Therapeutics (LOGC), La Jolla Pharmaceutical (LJPC), Allena Pharmaceuticals (ALNA), Jounce Therapeutics (JNCE), ADMA Biologics (ADMA), Compugen (CGEN), Neon Therapeutics (NTGN), Surface Oncology (SURF), Fennec Pharmaceuticals (FENC), Erytech Pharma (ERYP), Organovo (ONVO), Pluristem Therapeutics (PSTI), Champions Oncology (CSBR) and Nantkwest (NK).
Who are Applied Genetic Technologies' key executives?
Applied Genetic Technologies' management team includes the folowing people:
- Ms. Susan B. Washer, Pres, CEO & Director (Age 57)
- Mr. William A. Sullivan, Chief Financial Officer (Age 47)
- Dr. Matthew Feinsod, Interim Chief Medical Officer (Age 47)
- Dr. Nicholas Muzyczka, Co-Founder
- Dr. Barry J. Byrne, Co-Founder
How do I buy shares of Applied Genetic Technologies?
Shares of AGTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Applied Genetic Technologies' stock price today?
One share of AGTC stock can currently be purchased for approximately $3.04.
How big of a company is Applied Genetic Technologies?
Applied Genetic Technologies has a market capitalization of $56.93 million and generates $24.19 million in revenue each year. The biotechnology company earns $-21,300,000.00 in net income (profit) each year or ($1.18) on an earnings per share basis. Applied Genetic Technologies employs 78 workers across the globe.
What is Applied Genetic Technologies' official website?
How can I contact Applied Genetic Technologies?
Applied Genetic Technologies' mailing address is 14193 NW 119TH TERRACE SUITE 10, ALACHUA FL, 32615. The biotechnology company can be reached via phone at 386-462-2204.
MarketBeat Community Rating for Applied Genetic Technologies (NASDAQ AGTC)
MarketBeat's community ratings are surveys of what our community members think about Applied Genetic Technologies and other stocks. Vote "Outperform" if you believe AGTC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGTC will underperform the S&P 500 over the long term. You may vote once every thirty days.
